Genelux (GNLX) Payables (2022 - 2026)

Genelux (GNLX) posted quarterly Payables of $6.1 million for Q1 2026, up 39.86% quarter-over-quarter from $4.4 million in Q4 2025.

Genelux (GNLX) Payables (2022 - 2026) Analysis & Trends

Genelux's Payables history runs 5 years deep, the most recent figure standing at $6.1 million for Q1 2026.

In Q1 2026, Payables changed N/A year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (changed N/A YoY), while the FY2025 annual figure was $4.4 million, down 21.76% from the prior year.
Payables for Q1 2026 stood at $6.1 million, up from $4.4 million in the prior quarter.
The five-year high for Payables was $7.8 million in Q4 2022, with the low at $3.8 million in Q4 2023.
The 5-year median for Payables is $4.8 million (2024), against an average of $5.1 million.
The sharpest annual moves came in 2023 and 2024: Payables plunged 50.77% in 2023, then surged 45.66% in 2024.
Genelux's Payables stood at $7.8 million in 2022, then slumped by 50.77% to $3.8 million in 2023, then soared by 45.66% to $5.6 million in 2024, then dropped by 21.76% to $4.4 million in 2025, then soared by 39.86% to $6.1 million in 2026.
Business Quant data shows GNLX's Payables at $6.1 million in Q1 2026, $4.4 million in Q4 2025, and $4.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	108.02 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	428.93 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	35.57 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	622.65 Mn
10	Genelux	120.53 Mn	120.53 Mn	-	6.10 Mn

Download Data